Journal of Hypertension · 2006 · 22 citations · 35 references
MedicineCardiologyPharmacologyCardiovascular PharmacotherapyMolecular PharmacologyPharmacodynamicsCardiac MedicationsCardiac PharmacotherapyCardiovascular PharmacodynamicsCardiovascular PharmacologyHemodynamic PharmacologyAdrenergic AntagonistsAdrenergic Receptor AntagonistsAngiotensin Ii Receptor BlockersPharmacologic Metabolic EffectsPropranolol TherapyRenin-angiotensin System BlockadeRenin-angiotensin System ModulationRenin-angiotensin-aldosterone System Blockade
OBJECTIVE: To investigate whether renin-angiotensin system blockade might underlie the favorable metabolic effects of the nonselective beta + alpha1-adrenoceptor blocker carvedilol as compared with the selective beta1-adrenoceptor blocker metoprolol. METHODS: Human coronary microarteries (HCMAs), obtained from 32 heart valve donors, were mounted in myographs. RESULTS: Angiotensin II and the alpha1-adrenoceptor agonist phenylephrine constricted HCMAs to maximally 63 +/- 10 and 46 +/- 15% of the contraction to 100 mmol/l K. Neither carvedilol, metoprolol, the nonselective beta-adrenoceptor antagonist propranolol, nor the alpha1-adrenoceptor antagonist prazosin affected the constrictor response to angiotensin II. alpha1-adrenoreceptors and beta-adrenoceptors are thus not involved in the direct constrictor effects of angiotensin II. When added to the organ bath at a subthreshold concentration, angiotensin II greatly amplified the response to phenylephrine. Both carvedilol and the angiotensin II type 1 (AT1) receptor antagonist irbesartan inhibited this angiotensin II-induced potentiation. Furthermore, carvedilol blocked the angiotensin II-induced amplification of phenylephrine-induced inositol phosphate accumulation in cardiomyocytes. CONCLUSIONS: AT1-alpha1-receptor crosstalk, involving inositol phosphates, sensitizes HCMAs to alpha1-adrenoceptor agonists. Our results suggest that, in the presence of an increased sympathetic tone, carvedilol provides AT1 receptor blockade via its alpha1-adrenoceptor blocking effects. This could explain the favorable effects of carvedilol versus metoprolol.
35
Philip A. Poole‐Wilson, Karl Swedberg, John G.F. Cleland et al. · The Lancet · 2003 · 1.9K citations · Full text
Medicine, Cardiology, Pharmacology +13